About Maruthi Biosciences
Maruthi Biosciences is a Healthcare company. A company engaged in human organ transplantation and healthcare innovations in India. Its Indian entity Maruthi Biosciences Private Limited reported revenue of ₹1.58 Cr. Maruthi Biosciences offers products and services including Rencept 360 and Imugraf 1/0.5 mg. Its focus areas include Biotechnology, Organ Transplantation, Immunoadsorption Technology and Medical Services.
Company details
Maruthi Biosciences Private Limited is noted as having been incorporated in 2009 with a focus on human organ transplantation. It is aimed at pioneering in this field by the next decade, primarily serving the patient community in India, which is recognized as an emerging destination for medical tourism. The company is formed by professionals from the pharma and healthcare sectors, who have contributed decades of experience. Key developments include the announcement of Indias first ABO incompatible kidney transplant using immuno adsorption technology and the initiation of operations in Karnataka via medical symposia, alongside offerings like Rencept 360 and Imugraf.
- SectorsHealthcare
- Legal Name Maruthi Biosciences Private Limited
- Date of Incorporation 29 Jun, 2009
- Jurisdiction Hyderabad, Telangana, India
- Indian entity revenue₹1.58 Cr
FY 2024 · +24% YoY
- Indian entity net loss-₹3.4 Lakh
FY 2024 · -2% margin
- Indian entity EBITDA₹24.5 Lakh
FY 2024 · 15% margin
Associated legal entities of Maruthi Biosciences
Maruthi Biosciences operates through Maruthi Biosciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Maruthi Biosciences Private Limited CIN U24232TG2009PTC064184 | Active | 29 Jun 2009 | Hyderabad, Telangana | ₹1.6 Cr | 2 | View details |
Products & Services of Maruthi Biosciences
Maruthi Biosciences offers a comprehensive portfolio of products and services, including Rencept 360 and Imugraf 1/0.5 mg.
Rencept 360 is utilized in organ transplantation processes.
Imugraf 1/0.5 mg is employed in immuno suppression for transplantation-related applications.
Board of directors of Maruthi Biosciences Private Limited (Maruthi Biosciences)
Maruthi Biosciences Private Limited is the primary company behind Maruthi Biosciences. The board of Maruthi Biosciences Private Limited currently have 2 directors; the longest-serving is Balantrapu Rao Venkateswar, appointed in 2009.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Balantrapu Rao Venkateswar DIN 02655025 | Director | 29 Jun 2009 | 17 yrs 3 mo | Maruthi Biosciences Private Limited |
| Balantrapu Anita DIN 02655017 | Director | 29 Jun 2009 | 17 yrs 3 mo | Maruthi Biosciences Private Limited |
Financials of Maruthi Biosciences
Figures of Maruthi Biosciences Private Limited, the primary company behind Maruthi Biosciences, for FY 2024. Revenue was ₹1.58 Cr (+24% year on year). Net loss was -₹3.4 Lakh (-2% margin). EBITDA was ₹24.5 Lakh (15% margin). Revenue has grown at a compounded annual rate of +15% over three years and +8% over five years.
- ₹1.58 CrRevenue · FY 2024 · +24% YoY
- -₹3.4 LakhNet loss · -2% margin
- ₹24.5 LakhEBITDA · 15% margin
- ₹3 LakhPaid-up capital
- +15%Revenue CAGR, 3 years
- +8%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Maruthi Biosciences Private Limited are on its company page.
Detailed financial statements for Maruthi Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Maruthi Biosciences
The primary company behind Maruthi Biosciences, Maruthi Biosciences Private Limited, reported revenue of ₹1.58 Cr for FY 2024, up 24% year on year.
Maruthi Biosciences Private Limited is noted as having been incorporated in 2009 with a focus on human organ transplantation. It is aimed at pioneering in this field by the next decade, primarily serving the patient community in India, which is recognized as an emerging destination for medical tourism. The company is formed by professionals from the pharma and healthcare sectors, who have contributed decades of experience. Key developments include the announcement of Indias first ABO incompatible kidney transplant using immuno adsorption technology and the initiation of operations in Karnataka via medical symposia, alongside offerings like Rencept 360 and Imugraf.
Maruthi Biosciences offers Rencept 360 and Imugraf 1/0.5 mg.
Maruthi Biosciences operates through Maruthi Biosciences Private Limited.
The legal entities of Maruthi Biosciences currently have 2 directors, including Balantrapu Rao Venkateswar, Balantrapu Anita.